Table Info

Table 2.

Correlation of baseline and post-chemotherapy follow-up parameters with cfDNA detectability

Baseline and post-chemotherapy correlations	Parameters	Spearman coefficient	P value
Correlation of cfDNA detectability at baseline	Gender	–0.12	0.35
	ECOG status	0.19	0.16
	KPS	0.21	0.11
	Smoking status	0.04	0.77
	Smoking severity	–0.09	0.49
	TNM 8 stage	0.18	0.16
	Co-morbidities	0.04	0.76
	RSB score	0.05	0.71
	TSB score	0.05	0.71
	Weight change	–0.08	0.52
Correlation of cfDNA detectability at follow-up (post chemotherapy)	ECOG status	0.00	1.00
	KPS	0.10	0.60
	RSB score	–0.32	0.11
	TSB score	–0.10	0.60
	Weight change	0.10	0.63
	RECIST 1.1 change	–0.02	0.93

cfDNA: cell free DNA; ECOG: Eastern Co-operative Oncology Group; KPS: Karnofsky performance scale; TNM: tumor-nodes-metastasis; RSB: respiratory symptom burden; TSB: total symptom burden

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002232_sup_1.pdf.

Declarations

Author contributions

NR: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft, Writing—review & editing. PG: Investigation, Writing—original draft, Writing—review & editing, Validation. AB: Conceptualization, Methodology, Investigation, Writing—review & editing, Validation, Supervision. KTP, MG, and RK: Resources, Writing—review & editing, Supervision. NS: Conceptualization, Methodology, Formal analysis, Writing—original draft, Writing—review & editing, Validation, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study has been approved by the Ethics Committee PGIMER IEC. Reference No.: NK/4781/DM/188. This study complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The datasets for this manuscript are not publicly available because of institutional and national regulatory guidelines. However, reasonable requests for accessing the datasets should be directed to the corresponding author.

Funding

Not applicable.

Copyright

References

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157–64. [DOI] [PubMed]

Gedvilaitė V, Schveigert D, Cicėnas S. Cell-free DNA in non-small cell lung cancer. Acta Med Litu. 2017;24:138–44. [DOI] [PubMed] [PMC]

Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 2010;36:885–92. [DOI] [PubMed]

Katopodis P, Anikin V, Kishore U, Carter T, Hall M, Asadi N, et al. Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery. BMJ Open Respir Res. 2021;8:e000917. [DOI] [PubMed] [PMC]

Li BT, Drilon A, Johnson ML, Hsu M, Sima CS, McGinn C, et al. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Ann Oncol. 2016;27:154–9. [DOI] [PubMed] [PMC]

Levy B, Hu ZI, Cordova KN, Close S, Lee K, Becker D. Clinical utility of liquid diagnostic platforms in non-small cell lung cancer. Oncologist. 2016;21:1121–30. [DOI] [PubMed] [PMC]

Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006;52:1833–42. [DOI] [PubMed]

Goto T, Hirotsu Y, Amemiya K, Nakagomi T, Shikata D, Yokoyama Y, et al. Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. Oncotarget. 2017;8:59268–81. [DOI] [PubMed] [PMC]

Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis. 2012;4:474–84. [DOI] [PubMed] [PMC]

10.

Yenge LB, Behera D, Garg M, Aggarwal AN, Singh N. Comparison of symptom score and bronchoscopy-based assessment with conventional computed tomography-based assessment of response to chemotherapy in lung cancer. J Glob Oncol. 2016;3:370–9. [DOI] [PubMed] [PMC]

11.

Singh PS, Aggarwal AN, Behera D, Kapoor R, Singh N. Simplified graded baseline symptom assessment in patients with lung cancer undergoing first-line chemotherapy: correlations and prognostic role in a resource-constrained setting. J Glob Oncol. 2016;3:54–63. [DOI] [PubMed] [PMC]

12.

Kaur H, Sehgal IS, Bal A, Gupta N, Behera D, Das A, et al. Evolving epidemiology of lung cancer in India: Reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian J Cancer. 2017;54:285–90. [DOI] [PubMed]

13.

Singh N, Aggarwal AN, Behera D. Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Rev Anticancer Ther. 2012;12:1479–95. [DOI] [PubMed]

14.

Singh N, Singh PS, Aggarwal AN, Behera D. Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer. 2016;17:205–13.e1. [DOI] [PubMed]

15.

Singh N, Baldi M, Kaur J, Muthu V, Prasad KT, Behera D, et al. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: the PEMVITASTART randomized trial. Cancer. 2019;125:2203–12. [DOI] [PubMed]

16.

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50. [PubMed]

17.

Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer. 2010;69:225–31. [DOI] [PubMed]

18.

Soliman SE, Alhanafy AM, Habib MSE, Hagag M, Ibrahem RAL. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Rep. 2018;15:45–51. [DOI] [PubMed] [PMC]

19.

Chiappetta C, Anile M, Leopizzi M, Venuta F, Della Rocca C. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer. Clin Chim Acta. 2013;425:93–6. [DOI] [PubMed]

20.

Hyun MH, Sung JS, Kang EJ, Choi YJ, Park KH, Shin SW, et al. Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer. Oncotarget. 2017;8:94417–30. [DOI] [PubMed] [PMC]

21.

Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer. 2014;110:363–8. [DOI] [PubMed] [PMC]

22.

Yoon KA, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 2009;11:182–5. [DOI] [PubMed] [PMC]

23.

Pontes NZ, Da Silva FF, Rodrigues YC, De Maichi, Lengert A, Reis R, et al. P1.03-36 cell-free DNA levels in liquid biopsy from patients with non-small cell lung cancer and association with clinical parameters and disease outcome. J Thorac Oncol. 2019;14:S432. [DOI]

24.

Santos E, Talebi T, Raez L, Quintero C, Walker G, Farias M, et al. Free circulating DNA by RT-PCR as predictor for chemotherapy response in newly diagnosed patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28:e18107. [DOI]

25.

Nygård L, Ahlborn LB, Persson GF, Chandrananda D, Langer JW, Fischer BM, et al. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients-initial observations. PLoS One. 2020;15:e0231884. [DOI] [PubMed] [PMC]

26.

Pan S, Xia W, Ding Q, Shu Y, Xu T, Geng Y, et al. Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer? Biomed Pharmacother. 2012;66:131–7. [DOI] [PubMed]

27.

Vinayanuwattikun C, Winayanuwattikun P, Chantranuwat P, Mutirangura A, Sriuranpong V. The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol. 2013;139:67–76. [DOI] [PubMed]

28.

Davis A, Iams W, Chan D, Oh M, Lentz R, Peterman N, et al. P1.01-49 serial changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced NSCLC. J Thorac Oncol. 2019:14:S377. [DOI]

29.

Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, et al. Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy. Int J Mol Sci. 2017;18:1035. [DOI] [PubMed] [PMC]

30.

Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015;46:1773–80. [DOI] [PubMed]

31.

Cargnin S, Canonico PL, Genazzani AA, Terrazzino S. Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival: a systematic review and meta-analysis. J Thorac Oncol. 2017;12:43–53. [DOI] [PubMed]

32.

Singh N, Agrawal S, Jiwnani S, Khosla D, Malik PS, Mohan A, et al. Lung cancer in India. J Thorac Oncol. 2021;16:1250–66. [DOI] [PubMed]